TY - JOUR AU - Ma, Ke AU - Gu, Zhitao AU - Han, Yongtao AU - Fu, Jianhua AU - Shen, Yi AU - Wei, Yucheng AU - Tan, Lijie AU - Zhang, Peng AU - Chen, Chun AU - Zhang, Renquan AU - Li, Yin AU - Chen, Keneng AU - Chen, Hezhong AU - Liu, Yongyu AU - Cui, Youbing AU - Wang, Yun AU - Pang, Liewen AU - Yu, Zhentao AU - Zhou, Xinming AU - Liu, Yangchun AU - Liu, Yuan AU - Fang, Wentao AU - Research in Thymomas, Members of the Chinese Alliance for PY - 2016 TI - The application of postoperative chemotherapy in thymic tumors and its prognostic effect JF - Journal of Thoracic Disease; Vol 8, No 4 (April 01, 2016): Journal of Thoracic Disease [Thymic Malignancy—Perspectives from the Chinese Alliance for Research in Thymomas (ChART)] Y2 - 2016 KW - N2 - Background: To study the role of postoperative chemotherapy and its prognostic effect in Masaoka-Koga stage III and IV thymic tumors. Methods: Between 1994 and 2012, 1,700 patients with thymic tumors who underwent surgery without neoajuvant therapy were enrolled for the study. Among them, 665 patients in Masaoka-Koga stage III and IV were further analyzed to evaluate the clinical value of postoperative chemotherapy. The Kaplan-Meier method was used to obtain the survival curve of the patients divided into different subgroups, and the Cox regression analysis was used to make multivariate analysis on the factors affecting prognosis. A Propensity-Matched Study was used to evaluate the clinical value of chemotherapy. Results: Two-hundred and twenty-one patients were treated with postoperative chemotherapy, while the rest 444 cases were not. The two groups showed significant differences (P Conclusions: Pathologically higher grade histology, incomplete resection, and postoperative radiotherapy were found to be associated with worse outcomes in advanced stage thymic tumors. At present, there is no evidence to show that postoperative chemotherapy may help improve prognosis in patients with Masaoka-Koga stage III and IV thymic tumors. UR - https://jtd.amegroups.org/article/view/6964